Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | KMT2A fusion |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07223814 | Phase III | Cytarabine + Daunorubicin Bleximenib + Cytarabine + Idarubicin Cytarabine + Idarubicin Bleximenib + Cytarabine + Daunorubicin | Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) | Recruiting | USA | NLD | DEU | 0 |
| NCT02487459 | Phase I | Rivogenlecleucel Rimiducid | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | Withdrawn | USA | 0 |
| NCT07355335 | Phase I | CC-92480 + Ziftomenib | Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML | Not yet recruiting | USA | 0 |
| NCT04988555 | Phase Ib/II | DSP-5336 DSP-5336 + Fluconazole Azacitidine + DSP-5336 + Venetoclax DSP-5336 + Gilteritinib Azacitidine + DSP-5336 + Fluconazole + Venetoclax | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Recruiting | USA | ITA | GBR | FRA | ESP | CHE | CAN | BEL | 4 |